News
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback